In a display of scientific willpower, A*STAR researchers developed and deployed the COVID-19 diagnostic Fortitude Kit within weeks of the virus reaching Singapore’s shores.
Two linear peptides identified by A*STAR researchers on the SARS-CoV-2 spike protein may improve the specificity of serological assays and show potential as vaccine candidates.
Curiox Biosystems, an A*STAR spin-off company, specializes in automated and quantitative cell analysis. Its CEO, Namyong Kim, shares the story of the company’s success.